The Biology and Diagnosis of Ochronosis
At a Glance
Ochronosis diagnosis depends on its cause: inherited alkaptonuria is evaluated with a measured urine homogentisic acid test and sometimes HGD gene testing, while acquired skin disease is assessed through product history, skin examination, and biopsy; imaging provides supporting clues.
Understanding how ochronosis happens requires looking deep into your body’s chemistry. Whether the condition is inherited or caused by a cream, the result is the buildup of a pigment that your body cannot easily clear. However, the “how” and “where” of this buildup are what your medical team must pinpoint to give you the right care [1].
The Chemistry of “Endogenous” Ochronosis (AKU)
In the genetic form, Alkaptonuria (AKU), the issue starts with an autosomal recessive mutation in the HGD gene [2]. This means you inherited two copies of a non-working gene, one from each parent.
This gene is responsible for making an enzyme called homogentisate 1,2-dioxygenase. Think of this enzyme as a specialized biological “shredder.” Its job is to break down homogentisic acid (HGA), a byproduct of processing proteins [3][4]. When the “shredder” is broken:
- Accumulation: HGA levels in the blood and urine rise significantly [2].
- Oxidation: As HGA sits in your tissues, it reacts with oxygen (oxidizes) and begins to link together (polymerize) [5][6].
- Tissue Deposition: This new polymer turns into a dark, ink-like pigment that physically binds to collagen, the structural protein in your skin, heart valves, and joints [7][2].
The Chemistry of “Exogenous” Ochronosis (EO)
The acquired form does not involve a “broken shredder” in your blood. Instead, it is a localized reaction on the skin’s surface. When you apply agents like hydroquinone, phenol, or resorcinol, researchers propose that they may interfere with an enzyme in your skin called tyrosinase [8][9].
Under certain conditions—usually long-term use of high concentrations—these chemicals may produce byproducts that reach the deeper layer of the skin (the dermis). Histologic observations suggest these byproducts polymerize into dark pigment particles that get trapped between your skin’s collagen fibers, creating a pigment that looks very similar to AKU [10][11]. This mechanism, however, is complex and not fully understood.
Diagnostic Tests
To know which type you have, doctors use specific tests alongside your clinical history.
- For AKU (Genetic): The central biochemical test is a quantitative urinary HGA test. A lab uses a technique called HPLC (high-performance liquid chromatography) to measure the exact amount of HGA in your urine [2][12]. Genetic testing of the HGD gene can further confirm the diagnosis and help with family risk assessment [13]. Note that if a patient is already taking treatment like nitisinone, urinary HGA may be suppressed.
- For EO (Acquired): A skin biopsy can support the diagnosis but is not always required. A pathologist looks under a microscope for yellow-brown deposits. In some cases, these look like tiny, curved banana bodies or sickle-shaped fibers wedged between collagen bundles [14][11]. The absence of the phrase “banana bodies” does not invalidate a pathology report.
- Dermoscopy: Your dermatologist may use a handheld magnifying tool (dermoscopy) to look for “blue-gray” globules or “comma-shaped” structures, which can suggest exogenous ochronosis [15][16].
Common Diagnostic Pitfalls
Ochronosis is frequently mistaken for other more common conditions. Knowing the differences can save you from incorrect treatments.
The “Pseudo-Blood” Trap
In AKU, the urine often turns black when left to sit or when exposed to alkaline substances (like certain soaps). This is sometimes mistaken for hematuria (blood in the urine). A standard dipstick test for blood will come back negative if the color is purely from HGA [2][17]. However, dark urine can also result from dehydration, actual blood, muscle breakdown, or medications. You should always have new, unexplained dark or red urine medically evaluated rather than assuming it is HGA.
The Spinal Disease Mix-up
The spinal damage in AKU can look remarkably like ankylosing spondylitis (an inflammatory arthritis) on a standard X-ray. Both cause stiffness and a “fused” appearance, but there are supportive clues that point to ochronosis:
- Wafer-like Calcification: In ochronosis, the calcification frequently happens right in the center of the spinal discs, looking like thin white “wafers.” [2][18].
- Sacroiliac (SI) Joint Sparing: In most cases of ochronosis, the joints at the base of the spine (SI joints) remain clear and healthy early on. In ankylosing spondylitis, these joints are almost always the first to show damage [2][19].
These imaging features are supportive findings, not a substitute for full biochemical testing.
What Your Reports Should Say
Ensure your records include:
- Lab Report: A quantitative value for urinary HGA, not just a “present/absent” dipstick result [2].
- Pathology Report: If a biopsy was done, it should describe the pigment and the specific layer of skin where it was found [14][20].
- Imaging Report: For spinal X-rays or MRIs/CTs, it should note whether the intervertebral discs are calcified and if there is a vacuum-disc phenomenon (air pockets in the disc), which is common in AKU [21][22].
Common questions in this guide
What causes ochronosis?
What test confirms inherited ochronosis or alkaptonuria?
Why can urine turn black in alkaptonuria?
Can a skin biopsy diagnose exogenous ochronosis?
Which creams or chemicals can cause exogenous ochronosis?
What imaging findings help distinguish ochronosis from ankylosing spondylitis?
What should be included in an ochronosis diagnostic report?
Get notified when new evidence is published on ochronosis disorder.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (22)
- 1
Alkaptonuria.
Bernardini G, Braconi D, Zatkova A, et al.
Nature reviews. Disease primers 2024; (10(1)):16 doi:10.1038/s41572-024-00498-x.
PMID: 38453957 - 2
A Mimic of Ankylosing Spondylitis, Ochronosis: Case Report and Review of the Literature.
Chu P, Cuellar MC, Bracken SJ, Tarrant TK
Current allergy and asthma reports 2021; (21(3)):19 doi:10.1007/s11882-021-01002-1.
PMID: 33666743 - 3
Presentation of 14 alkaptonuria patients from Turkey.
Akbaba AI, Ozgül RK, Dursun A
Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(2)):289-294.
PMID: 31927521 - 4
Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and genotype-phenotype correlations in the largest cohort of patients with AKU.
Ascher DB, Spiga O, Sekelska M, et al.
European journal of human genetics : EJHG 2019; (27(6)):888-902 doi:10.1038/s41431-019-0354-0.
PMID: 30737480 - 5
Ochronotic Deposition in Alkaptonuria: Semiquinone-Mediated Oxidative Coupling and Metabolic Drivers of Homogentisic Acid Accumulation.
Grasso D, Balloni V, Baratto MC, et al.
International journal of molecular sciences 2025; (26(19)) doi:10.3390/ijms26199674.
PMID: 41096940 - 6
A molecular spectroscopy approach for the investigation of early phase ochronotic pigment development in Alkaptonuria.
Bernini A, Petricci E, Atrei A, et al.
Scientific reports 2021; (11(1)):22562 doi:10.1038/s41598-021-01670-z.
PMID: 34799606 - 7
Anatomical Distribution of Ochronotic Pigment in Alkaptonuric Mice is Associated with Calcified Cartilage Chondrocytes at Osteochondral Interfaces.
Hughes JH, Keenan CM, Sutherland H, et al.
Calcified tissue international 2021; (108(2)):207-218 doi:10.1007/s00223-020-00764-6.
PMID: 33057760 - 8
Exogenous ochronosis by hydroquinone is not caused by inhibition of homogentisate dioxygenase but potentially by tyrosinase-catalysed metabolism of hydroquinone.
Ito S, Kolbe L, Weets G, et al.
The British journal of dermatology 2025; (193(5)):959-967 doi:10.1093/bjd/ljaf273.
PMID: 40662524 - 9
Exogenous Ochronosis With Ocular Involvement From Chronic Use of Teavigo.
Vempuluru VS, Laiton A, Milman T, et al.
Ophthalmic plastic and reconstructive surgery 2023; (39(5)):e139-e142 doi:10.1097/IOP.0000000000002395.
PMID: 37010051 - 10
Mechanistic Insights into Tyrosinase-Catalyzed Metabolism of Hydroquinone: Implications for the Etiology of Exogenous Ochronosis and Cytotoxicity to Melanocytes.
Ito S, Kolbe L, Rogers T, et al.
International journal of molecular sciences 2025; (26(21)) doi:10.3390/ijms262110734.
PMID: 41226769 - 11
Exogenous ochronosis associated with hydroquinone: a systematic review.
Ishack S, Lipner SR
International journal of dermatology 2022; (61(6)):675-684 doi:10.1111/ijd.15878.
PMID: 34486734 - 12
Quick Diagnosis of Alkaptonuria by Homogentisic Acid Determination in Urine Paper Spots.
Jacomelli G, Micheli V, Bernardini G, et al.
JIMD reports 2017; (31()):51-56 doi:10.1007/8904_2016_554.
PMID: 27074788 - 13
Alkaptonuria in Russia.
Soltysova A, Kuzin A, Samarkina E, Zatkova A
European journal of human genetics : EJHG 2022; (30(2)):237-242 doi:10.1038/s41431-021-00955-1.
PMID: 34504318 - 14
[Exogenous ochronosis: An underdiagnosed cause of acquired facial hyperpigmentation].
Pelloux M, Lesport C, Guinet É, Gil H
Annales de pathologie 2026; doi:10.1016/j.annpat.2026.08.001.
PMID: 42648955 - 15
Clinical and dermoscopic characteristics of exogenous ochronosis: results of a multicentre study by the International Dermoscopy Society Dermoscopy in Skin of Color Task Force.
Vinay K, Mehta H, Bhat YJ, et al.
Clinical and experimental dermatology 2025; (50(9)):1777-1785 doi:10.1093/ced/llaf159.
PMID: 40186504 - 16
Clinical and Dermoscopic Characteristics of Facial Hyperpigmentation Disorders in Skin of Color.
Mansilla-Polo M, Díaz-Gómez CJ, Morgado-Carrasco D
Actas dermo-sifiliograficas 2026; (117(7)):104637 doi:10.1016/j.ad.2026.104637.
PMID: 41865981 - 17
Alkaptonuria in Turkey: Clinical and molecular characteristics of 66 patients.
Kisa PT, Gunduz M, Dorum S, et al.
European journal of medical genetics 2021; (64(5)):104197 doi:10.1016/j.ejmg.2021.104197.
PMID: 33746036 - 18
"As Black as Ink": A Case of Alkaptonuria-Associated Myelopathy and a Review of the Literature.
Donaldson CJ, Mitchell SL, Riley LH, Kebaish KM
Spine 2019; (44(1)):E53-E59 doi:10.1097/BRS.0000000000002755.
PMID: 29933333 - 19
Inflammatory rheumatic diseases in patients with ochronotic arthropathy.
Yuce Inel T, Kisa PT, Balci A, et al.
Modern rheumatology 2021; (31(5)):1031-1037 doi:10.1080/14397595.2020.1868121.
PMID: 33427541 - 20
Exogenous ochronosis: the failure of depigmenting creams.
Sánchez-Martínez EM, García-Briz MI, Moneva-Léniz LM, et al.
Dermatology online journal 2019; (25(4)).
PMID: 31046915 - 21
Management of a pseudarthrosis with sagittal malalignment in a patient with ochronotic spondyloarthropathy.
Alkasem W, Boissiere L, Obeid I, Bourghli A
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 2019; (28(10)):2283-2289 doi:10.1007/s00586-019-06020-2.
PMID: 31175484 - 22
Musculoskeletal Manifestations of Alkaptonuria: A Case-Based Review of Literature.
K A, Kumar S, M V B, et al.
Cureus 2025; (17(8)):e90841 doi:10.7759/cureus.90841.
PMID: 40995248
This page explains how ochronosis develops and how it is diagnosed for informational purposes only and does not constitute medical advice. Ask your healthcare professional to interpret your urine, genetic, biopsy, and imaging results.